GLP-1 (7-37)
The native, full-length active form of glucagon-like peptide-1 — the endogenous incretin hormone that the entire GLP-1 receptor agonist drug class is modeled on.
GLP-1(7-37) is the native 30-amino-acid active form of glucagon-like peptide 1, an endogenous incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Acting at GLP-1 receptors in the pancreas, gut, and brain, it stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite, and helps protect beta-cell mass. It is the endogenous ligand underlying the pharmacology of the modern GLP-1 receptor agonist class, but its ~2-minute half-life limits its use to continuous infusion and research settings.
Class
Endogenous incretin peptide hormone (native GLP-1, 30 amino acids)
Half-life
Approximately 2 minutes, due to rapid degradation by DPP-IV
Routes
Subcutaneous (continuous infusion), Intravenous (continuous infusion)
Category
Weight Loss & Metabolic
Researched benefits
What it's studied for
Glucose-dependent insulin secretion
Activates cAMP/PKA signaling in pancreatic beta cells to potentiate insulin release strictly during hyperglycemia. Because the effect is glucose-dependent, it provides intrinsic protection against hypoglycemia. Demonstrated in a randomized crossover infusion trial in type 2 diabetics.
Blood glucose regulation
Continuous native GLP-1(7-37) infusion reduced fasting blood glucose in obese patients with type 2 diabetes, establishing the metabolic basis for GLP-1 receptor agonism as a therapeutic strategy.
Glucagon suppression
Suppresses glucagon release from pancreatic alpha cells, reducing hepatic glucose output and contributing to improved glycemic control.
Appetite suppression
Central GLP-1 receptor activation in hypothalamic appetite-regulating neurons reduces caloric intake through satiety signaling; reduced appetite was observed during continuous infusion in humans.
Improved insulin responsiveness
In a clinical trial, GLP-1(7-37) improved insulin responsiveness in part by reducing pre-hepatic insulin extraction, enhancing the efficiency of endogenous insulin.
Beta-cell protection
Native GLP-1 signaling is associated with preservation of beta-cell mass, a mechanism of interest for the incretin hormone class.
Mechanism
How it works
GLP-1(7-37) is the native active form of glucagon-like peptide 1, an incretin hormone released by intestinal L-cells after nutrient ingestion. It binds GLP-1 receptors expressed throughout the body — on pancreatic beta cells, hypothalamic appetite-regulating neurons, gastric enteric neurons, and cardiovascular tissue.
In pancreatic beta cells it activates cAMP/PKA signaling to potentiate insulin release. Critically, this potentiation occurs only during hyperglycemia, making insulin secretion glucose-dependent and giving the peptide intrinsic hypoglycemia protection. It simultaneously suppresses glucagon release and slows gastric emptying.
Centrally, GLP-1 receptor activation in the hypothalamus reduces caloric intake via satiety signaling, accounting for the appetite-suppressing effect observed in human infusion studies.
The native peptide has a very short plasma half-life of about 2 minutes because it is rapidly degraded by the enzyme DPP-IV. This pharmacokinetic limitation makes continuous infusion the only practical route for the native form and is the reason the approved GLP-1 drug class consists of DPP-IV-resistant, chemically modified analogs rather than native GLP-1(7-37) itself.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Research (clinical infusion)
- Dose
- Not specified in available sources (delivered by continuous infusion)
- Frequency
- Continuous
- Timing
- Around-the-clock infusion
- Duration
- Reported in study over 48 hours
- Route
- Continuous subcutaneous or intravenous infusion
Because of the ~2-minute half-life, native GLP-1(7-37) is administered only as a continuous infusion; a 48-hour continuous infusion was used in the referenced type 2 diabetes trial. No fixed mcg/mg self-administration protocol is documented in the sources.
- Native GLP-1(7-37) cannot be dosed as a practical subcutaneous injection like the approved analogs — its ~2-minute half-life requires continuous infusion.
- Used exclusively as a research/tool compound in metabolic pharmacology; it is not an FDA-approved therapeutic.
- Those seeking a practical GLP-1 therapy typically use DPP-IV-resistant analogs (semaglutide, liraglutide, tirzepatide) rather than the native peptide.
Evidence
Research & clinical studies (2)
GLP-1 treatment of obese patients with type 2 diabetes mellitus: improvement of insulin responsiveness by reduction of pre-hepatic insulin extraction
In a small randomized crossover trial (n=6), continuous 48-hour GLP-1(7-37) infusion reduced fasting blood glucose, stimulated insulin secretion, suppressed glucagon, and reduced appetite in obese type 2 diabetics, establishing the metabolic basis for GLP-1 receptor agonism.
PMID 10388979Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli
Engineered compact fusion tags improved recombinant expression and recovery of GLP-1(7-37) precursors in E. coli; a 4.0 kDa tag (LP8) achieved the highest yields, offering a scalable manufacturing approach for GLP-1 analogs.
PMID 42124529Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Thyroid condition
- Pregnant or nursing
Generally considered lower risk in research contexts. Because insulin stimulation is glucose-dependent, the native peptide carries intrinsic protection against hypoglycemia. Individual response varies — review all contraindications before use and consult a qualified healthcare professional.
FAQ
GLP-1 (7-37) — common questions
What is GLP-1 (7-37)?
GLP-1(7-37) is the native 30-amino-acid active form of glucagon-like peptide 1, an endogenous incretin hormone secreted by intestinal L-cells after eating. It acts at GLP-1 receptors throughout the body to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, reduce appetite, and protect beta-cell mass. It is the endogenous ligand underlying the entire GLP-1 receptor agonist drug class.
How is GLP-1 (7-37) different from semaglutide or tirzepatide?
GLP-1(7-37) is the unmodified native peptide with a ~2-minute half-life, so it must be given by continuous infusion. Semaglutide, liraglutide, dulaglutide, and tirzepatide are chemically modified, DPP-IV-resistant analogs engineered to overcome that short half-life, allowing convenient injectable dosing.
What is GLP-1 (7-37) primarily studied for?
Appetite suppression, insulin sensitivity, and blood glucose regulation.
Why does GLP-1 (7-37) need continuous infusion?
It has a very short plasma half-life of about 2 minutes because DPP-IV rapidly degrades it. Continuous subcutaneous or intravenous infusion is the only practical way to maintain effective levels of the native peptide.
Does GLP-1 (7-37) cause hypoglycemia?
Its insulin-stimulating effect is glucose-dependent — it potentiates insulin release strictly during hyperglycemia. This provides intrinsic protection against hypoglycemia.
Is GLP-1 (7-37) FDA-approved?
No. Native GLP-1(7-37) has not been evaluated or approved by the FDA and is used only as a research tool compound. The approved therapies in this class are modified analogs, not the native peptide.
What are the reported side effects and contraindications?
It is considered lower risk in research contexts. Reported contraindications and considerations include thyroid conditions and pregnancy or nursing. Consult a qualified healthcare professional before use.
